Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 2/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.56 |
| ▸ | TYR | P14679 | 1/20 | 0.51 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6455408 | 1.00 | SCN1A (0.56) | SCN1ASCN2ASCN3ATYRSERPINE1 | |
| SCHEMBL6456297 | 0.88 | TYR (0.52) | SCN1ASCN2ASCN3ATYRSERPINE1 | |
| SCHEMBL6456292 | 0.88 | TYR (0.52) | SCN1ASCN2ASCN3ATYRSERPINE1 | |
| SCHEMBL6455338 | 0.88 | TYR (0.49) | SCN1ASCN2ASCN3ATYRSERPINE1 | |
| SCHEMBL6455332 | 0.88 | TYR (0.49) | SCN1ASCN2ASCN3ATYRSERPINE1 | |
| SCHEMBL6450371 | 0.88 | TYR (0.49) | SCN1ASCN2ASCN3ATYRSERPINE1 | |
| SCHEMBL6450374 | 0.88 | TYR (0.49) | SCN1ASCN2ASCN3ATYRSERPINE1 | |
| SCHEMBL6455207 | 0.87 | TYR (0.51) | SCN1ASCN2ASCN3ATYRSERPINE1 | |
| SCHEMBL6455210 | 0.87 | TYR (0.51) | SCN1ASCN2ASCN3ATYRSERPINE1 | |
| SCHEMBL6455534 | 0.86 | TYR (0.48) | SCN1ASCN2ASCN3ATYRSERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | claimed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | claimed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | claimed |
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050143594-A1 | Process for preparing resorcinol derivatives | BRADLEY STUART E (GB) | 2005-06-30 | — | — | US | disclosed |
| US-6861564-B2 | Process for preparing resorcinol derivatives | PFIZER INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20030088113-A1 | Process for preparing resorcinol derivatives | BRADLEY STUART EDWARD (GB) | 2003-05-08 | — | — | US | disclosed |
| US-6504037-B2 | Reacting a cyclohexanedione or chromene-one derivative with 1,8-diazabicyclo(5.4.0)undec-7ene | WARNER-LAMBERT COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020032352-A1 | Process for preparing resorcinol derivatives | PFIZER PRODUCTS INC. | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143594-A1 | Process for preparing resorcinol derivatives | CYP4B1, CYP4A11, POR | SCN1A 4173/4885SCN2A 3439/4885SCN3A 4238/4885 |
| US-20030088113-A1 | Process for preparing resorcinol derivatives | CYP4B1, CYP4A11, POR | SCN1A 4173/4885SCN2A 3439/4885SCN3A 4238/4885 |
| US-20040209949-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | SCN1A 3476/4885SCN2A 2317/4885SCN3A 4076/4885 |
| US-20020032352-A1 | Process for preparing resorcinol derivatives | CYP4B1, CYP4A11, POR | SCN1A 4173/4885SCN2A 3439/4885SCN3A 4238/4885 |
| US-20020161041-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | SCN1A 3476/4885SCN2A 2317/4885SCN3A 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.